Stock Events

Stock Events

Poniard Pharmaceuticals

€0

0

+€0+0% Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NX1B.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Amgen is a biotechnology firm focused on human therapeutics, directly competing in the oncology segment with Poniard Pharmaceuticals.

Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company with a strong portfolio in cancer drugs, overlapping with Poniard's focus on oncology treatments.

Pfizer is involved in the development and commercialization of various pharmaceuticals, including cancer treatments, which competes with Poniard's oncology products.

Merck is a leading pharmaceutical company with a significant presence in the oncology market, directly competing with Poniard Pharmaceuticals in cancer treatment solutions.

Eli Lilly and Company develops and sells pharmaceutical products, including cancer therapies, competing in the same space as Poniard Pharmaceuticals.

Gilead Sciences

Gilead Sciences is a biopharmaceutical company that develops and markets therapies in areas including oncology, competing with Poniard's cancer focus.

Novartis is a global healthcare company that manufactures drugs, including those for cancer, which places them in direct competition with Poniard Pharmaceuticals.

AstraZeneca operates in various therapeutic areas, including oncology, making them a competitor to Poniard Pharmaceuticals in the cancer drug market.

Roche Holding AG focuses extensively on oncology drug development and marketing, competing with Poniard Pharmaceuticals in the cancer treatment arena.

Johnson & Johnson

Johnson & Johnson engages in the creation of pharmaceuticals, including oncology drugs, competing with Poniard Pharmaceuticals in the healthcare sector.

About

Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.

Show more...

CEO

Dr. Robert F. Caspari

Employees

7

Country

United States

ISIN

US7324494001

Listings

0 Comments

Share your thoughts

FAQ

What is Poniard Pharmaceuticals stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Poniard Pharmaceuticals stocks are traded under the ticker NX1B.STU.

How many employees does Poniard Pharmaceuticals have?▼

As of May 06, 2026, the company has 7 employees.

In which sector is Poniard Pharmaceuticals located?▼

Poniard Pharmaceuticals operates in the Health & Wellness sector.

When did Poniard Pharmaceuticals complete a stock split?▼

Poniard Pharmaceuticals has not had any recent stock splits.

Where is Poniard Pharmaceuticals headquartered?▼

Poniard Pharmaceuticals is headquartered in Seattle, United States.